计算溶液所需的质量、体积或浓度。
| 活性类型 | 活性值-log(M) | 作用机制 | 期刊 | 参考文献(PubMed IDs) |
|---|
Livmoniplimab (anti-LRRC32/TGFβ1) 是一种有效的人源化抗 LRRC32 (GARP)/TGFβ1 复合体的单克隆抗体。Livmoniplimab (anti-LRRC32/TGFβ1) 阻断 LRRC32 介导的潜在 TGFβ1 激活和释放。Livmoniplimab (anti-LRRC32/TGFβ1) 具有癌症研究的潜力,可作为单一抗癌剂或与抗 PD-1 mAb 联合抑制局部晚期或转移性实体瘤 (NCT03821935)。
Livmoniplimab (anti-LRRC32/TGFβ1) is a potent, humanized monoclonal antibody against the LRRC32 (GARP)/TGFβ1 complex. Livmoniplimab (anti-LRRC32/TGFβ1) blocks LRRC32-mediated latent TGFβ1 activation and release. Livmoniplimab (anti-LRRC32/TGFβ1) has potential in cancer research as a single anticancer agent or in combination with an anti-PD-1 mAb to inhibit locally advanced or metastatic solid tumors (NCT03821935).
Purity
≥95% (SDS-PAGE&SEC)
Endotoxin Level
≤1.0EU/mg
Protein Function
TGFβ1: Multifunctional protein that controls proliferation, differentiation and other functions in many cell types. Many cells synthesize TGFB1 and have specific receptors for it. It positively and negatively regulates many other growth factors. It plays an important role in bone remodeling as it is a potent stimulator of osteoblastic bone formation, causing chemotaxis, proliferation and differentiation in committed osteoblasts.
| 作用机制 | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | 参考文献 |
|---|
我们的级别选择指南涵盖了目录中所有的变体的纯度、稳定剂状态和应用适用性。
查看 Animal Free 级别指南 → 查看 Carrier Free 级别指南 → 查看 Recombinant 级别指南 → 查看 Validated 级别指南 → 查看 ExactAb™ 级别指南 → 查看 Low Endotoxin 级别指南 → 查看 Azide Free 级别指南 →